Quantcast

Industry news that matters to you.  Learn more

First Blood Biomarker Discovered for the Prognosis of Multiple Sclerosis: Quick, Accurate and Soon to be Available

An international study, led by Macquarie University researchers Dr Edwin Lim and Professor Gilles Guillemin, has discovered the first blood biomarker – a chemical identifier in the blood – for multiple sclerosis (MS), a debilitating disorder of the central nervous system that affects more than 23,000 Australians and 2.3 million people worldwide.

Serum micoRNAs May Serve as Biomarkers for Multiple Sclerosis

MicroRNAs are small RNA molecules that influence basic cellular processes and have been proposed as biomarkers for the diagnosis, progression and treatment of multiple sclerosis. In a new study conducted at the Ann Romney Center of Neurologic Diseases at Brigham and Women’s Hospital, researchers have found that serum microRNAs are linked to MRI findings in the brain and spinal cord in patients with MS. These findings suggest that microRNAs could serve as promising biomarkers for monitoring the progression of MS and could help to identify distinct underlying disease processes, such as inflammation and tissue destruction.

Regulus Achieves All Research Milestones in Collaboration with Biogen to Identify microRNA Biomarkers for Multiple Sclerosis

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has earned a fourth milestone payment in its collaboration with Biogen (NASDAQ: BIIB) related to progress in the companies’ research collaboration to identify microRNAs as biomarkers for multiple sclerosis (“MS”). To earn the milestone, Regulus’ microMarkersSM division used its robust technology platform and bioinformatics expertise to analyze the treatment effects of a Biogen relapsing MS drug on circulating microRNA profiles previously identified by Regulus.

KineMed Announces Agreement With EMD Serono to Identify Protein and Lipid Biomarkers For Multiple Sclerosis

KineMed, Inc. recently announced an agreement with EMD Serono to apply KineMed’s mass spectrometric Dynamic Proteomics and lipids platforms to the discovery of protein and lipid biomarkers for multiple sclerosis.

Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network

A team led by the Accelerated Cure Project for Multiple Sclerosis (ACP) has been approved for a funding award by the Patient-Centered Outcomes Research Institute (PCORI) to create the Multiple Sclerosis Patient-Powered Research Network (MS-PPRN). The MS-PPRN is one of 29 health data networks that were approved for a total of $93.5 million from PCORI to form the PCORnet: the National Patient-Centered Clinical Research Network, a new national resource that aims to boost the efficiency of health research.